<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.89136</article-id><article-id pub-id-type="publisher-id">ACM-27452</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180900000_16621664.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胱抑素C在老年脓毒症急性肾损伤患者中启动CBP治疗时机的价值
  The Value of Cystatin C in Initiating Continuous Blood Purification in Elderly Patients with Acute Renal Injury Due to Sepsis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>阳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>景霞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>春涛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>大鹏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>承德医学院，河北 承德</addr-line></aff><aff id="aff3"><addr-line>承德市中心医院，河北 承德</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2018</year></pub-date><volume>08</volume><issue>09</issue><fpage>813</fpage><lpage>818</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨应用血清胱抑素C在老年脓毒症急性肾损伤患者中启动连续性血液净化(Continuous blood purification, CBP)治疗时机的价值。用新型生物标记物血清胱抑素C来评估脓毒症AKI老年患者中的上机时间，观察患者的炎症因子清除情况、肾功能恢复情况以及预后。方法：采集2017年11月~2018年8月期间于承德市中心医院重症医学科诊断为脓毒症急性肾损伤患者(年龄&gt;65岁) 58例，其中存在CBP上机指征的为43例分为胱抑素C升高(&gt;1.03 mg/L)至12小时内行CBP治疗组为A组与胱抑素C升高(&gt;1.03 mg/L) 12~24小时内行CBP治疗组为B组，测定行CBP治疗前后的降钙素原、C反应蛋白，血清肌酐、尿量、血清胱抑素C水平平均值、乳酸水平、计算序贯器官衰竭sofa评分、急性生理与慢性健康APACHE II评分、格拉斯哥GCS评分，是否采用机械通气、是否使用血管活性药物、治疗转归(28天病死率) (Y或D)。结果： 1) A组和B组的年龄，性别，住院时间，BMI，尿量，APACHE II评分，GCS评分，SOFA评分，入院时是否机械通气的例数，是否用血管活性药物的例数，血清胱抑素C (cys-c)，C反应蛋白(CRP)，血清肌酐(scr)，乳酸，降钙素原(PCT) P值均大于0.05，即以上指标在治疗前A组和B组均无统计学差异。2) A组与B组在治疗后的感染指标血清降钙素原(PCT)、C-反应蛋白(CRP)、急性生理学及慢性健康状况评分(APACHE) II评分中P值 &lt; 0.05，即存在两组之间统计学差异，且A组指标明显优于B组。3) A组与B组在治疗后的肾功能恢复指标尿量，血清肌酐(scr)，血清胱抑素C (cys-c)的P值 &lt; 0.05，即存在统计学差异，且A组肾功能恢复水平指标优于B组。4) 28天生存率A组与B组的比，P值 &gt; 0.05，即28天生存率两组无统计学意义。结论：胱抑素C升高后12小时内的治疗组比胱抑素C升高后12~24小时内治疗组的炎症因子清除及肾功能恢复方面效果好，但对于患者的生存率并无改变。
    Objective: To investigate the value of serum cystatin C in initiating continuous blood purification (Continuous blood purification, CBP) in elderly patients with acute renal injury. A new biomarker, serum cystatin C, was used to evaluate the time of booster, renal function recovery and prognosis in elderly patients with sepsis AKI. Methods: From November 2017 to August 2018, 43 elderly pa-tients with acute renal injury of sepsis who were treated with CBP in Department of intensive Medicine, Chengde Central Hospital were divided into two groups: group A treated with increased cystatin C (&gt;1.03 mg/L) and treated with CBP within 12 hours; group B was treated with CBP within 12 - 24 hours with the increase of cystatin C (&gt;1.03 mg/L). The levels of procalcitonin C-reactive protein, serum creatinine, urine volume, serum cystatin C level, lactate level, sofa score of sequential organ failure, APACHE II score of acute physiological and chronic health and Glasgow GCS score were measured before and after CBP treatment; whether mechanical ventilation and vasoactive drugs are used or not, and the outcome (28-day mortality) (Y or D) were also checked. Results: 1) Age, sex, length of stay, urine volume, Apache II score and sofa score, patients with mechanical ventilation, vasoactive drugs, serum cystatin C (cys-c) C-reactive protein (CRP), serum creatinine (scr), lactic acid were measured in group A and B, respectively. The (PCT) P values of procalcitonin were higher than 0.05, which indicated that there was no statistical difference be-tween group A and group B before treatment. 2) The serum calcitonin proto (PCT) C-reactive pro-tein (CRP), acute physiology and chronic health status score (APACHE) II in group A were signifi-cantly higher than those in group B (P &lt; 0.05). 3) There was significant difference between group A and group B in urine volume, serum creatinine (scr), serum cystatin C (cys-c) (P &lt; 0.05), and the index of renal function recovery in group A was better than that in group B (P &lt; 0.05). 4) The 28-day survival rate of group A and group B was more than 0.05, that is, the survival rate of group A and group B had no statistical significance. Conclusion: The effect of the treatment group within 12 hours after the rise of cystatin C was better than that of the treatment group within 12 - 24 hours after the increase of cystatin C, but there was no change in the survival rate of the patients. 
  
 
</p></abstract><kwd-group><kwd>老年脓毒症，急性肾损伤，连续性血液净化，胱抑素C, Senile Sepsis</kwd><kwd> Acute Renal Injury</kwd><kwd> Continuous Blood Purification</kwd><kwd> Cystatin C</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>胱抑素C在老年脓毒症急性肾损伤患者中启动CBP治疗时机的价值<sup> </sup></title><p>刘阳<sup>1</sup>，周景霞<sup>2*</sup>，刘春涛<sup>2</sup>，周大鹏<sup>2</sup></p><p><sup>1</sup>承德医学院，河北 承德</p><p><sup>2</sup>承德市中心医院，河北 承德</p><disp-formula id="hanspub.27452-formula34"><graphic xlink:href="//html.hanspub.org/file/6-1570715x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年10月17日；录用日期：2018年11月1日；发布日期：2018年11月8日</p><disp-formula id="hanspub.27452-formula35"><graphic xlink:href="//html.hanspub.org/file/6-1570715x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨应用血清胱抑素C在老年脓毒症急性肾损伤患者中启动连续性血液净化(Continuous blood purification, CBP)治疗时机的价值。用新型生物标记物血清胱抑素C来评估脓毒症AKI老年患者中的上机时间，观察患者的炎症因子清除情况、肾功能恢复情况以及预后。方法：采集2017年11月~2018年8月期间于承德市中心医院重症医学科诊断为脓毒症急性肾损伤患者(年龄&gt;65岁) 58例，其中存在CBP上机指征的为43例分为胱抑素C升高(&gt;1.03 mg/L)至12小时内行CBP治疗组为A组与胱抑素C升高(&gt;1.03 mg/L) 12~24小时内行CBP治疗组为B组，测定行CBP治疗前后的降钙素原、C反应蛋白，血清肌酐、尿量、血清胱抑素C水平平均值、乳酸水平、计算序贯器官衰竭sofa评分、急性生理与慢性健康APACHE II评分、格拉斯哥GCS评分，是否采用机械通气、是否使用血管活性药物、治疗转归(28天病死率) (Y或D)。结果： 1) A组和B组的年龄，性别，住院时间，BMI，尿量，APACHE II评分，GCS评分，SOFA评分，入院时是否机械通气的例数，是否用血管活性药物的例数，血清胱抑素C (cys-c)，C反应蛋白(CRP)，血清肌酐(scr)，乳酸，降钙素原(PCT) P值均大于0.05，即以上指标在治疗前A组和B组均无统计学差异。2) A组与B组在治疗后的感染指标血清降钙素原(PCT)、C-反应蛋白(CRP)、急性生理学及慢性健康状况评分(APACHE) II评分中P值 &lt; 0.05，即存在两组之间统计学差异，且A组指标明显优于B组。3) A组与B组在治疗后的肾功能恢复指标尿量，血清肌酐(scr)，血清胱抑素C (cys-c)的P值 &lt; 0.05，即存在统计学差异，且A组肾功能恢复水平指标优于B组。4) 28天生存率A组与B组的比，P值 &gt; 0.05，即28天生存率两组无统计学意义。结论：胱抑素C升高后12小时内的治疗组比胱抑素C升高后12~24小时内治疗组的炎症因子清除及肾功能恢复方面效果好，但对于患者的生存率并无改变。</p><p>关键词 :老年脓毒症，急性肾损伤，连续性血液净化，胱抑素C</p><disp-formula id="hanspub.27452-formula36"><graphic xlink:href="//html.hanspub.org/file/6-1570715x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1570715x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-1570715x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>脓毒症是重症医学科中发生率高、死亡率高的疾病。年龄是脓毒症和严重脓毒症发生的独立预测因素 [<xref ref-type="bibr" rid="hanspub.27452-ref1">1</xref>] ，统计结果显示，危险年龄以65岁为界，65岁以上患脓毒症的患者是65岁以下者的13.1倍，占脓毒症患者的64.9%，基础疾病(高血压、糖尿病、冠心病、脑血管疾病)，住院前的状态(可生活自理、不可生活自理)，营养不良，虚弱，免疫衰老，这些危险因素使得老年人具有相对高的发生脓毒症倾向，而且，更易罹患脓毒症 [<xref ref-type="bibr" rid="hanspub.27452-ref2">2</xref>] 。体外血液净化治疗目前已成为脓毒症治疗的重要部分。连续性肾脏替代治疗是指一组体外血液净化的治疗技术，是所有连续、缓慢清除水分和溶质治疗方式的总称，具有血流动力学稳定、有效清除中大分子、改善炎症状态、精确控制容量负荷及调节免疫功能等多种优势 [<xref ref-type="bibr" rid="hanspub.27452-ref3">3</xref>] 。在治疗脓毒症方面，主要是通过持续性清除溶质对各脏器起到支持作用。但应何时开始CBP是当前SAKI研究中应该首先被解决的问题之一，ADQI曾建议：肌酐升高2倍，或肾小球滤过率降低 &gt; 50%，尿量 &lt; 0.5 ml (kg∙h)超过2小时予以连续性血液净化治疗，但尿素氮、肌酐、尿量等常用的肾功能指标有一定的滞后性，血肌酐易受到性别、年龄、肌肉容积、经饮食摄入的外源性肌酐的影响，尿量也易受利尿剂、容量状态等因素影响 [<xref ref-type="bibr" rid="hanspub.27452-ref4">4</xref>] 。因此脓毒症患者在此之前可能已经出现了炎症因子的大量释放。对于老年患者这种疾病进展迅速，易早期引起血流动力学不稳定的特点，CBP的早期介入可以起到免疫调剂的作用，特别是脓毒症老年患者存在免疫衰老的特点。合适的CBP治疗时机对于老年患者显得尤为重要 [<xref ref-type="bibr" rid="hanspub.27452-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.27452-ref6">6</xref>] 。本研究根据老年脓毒症急性肾损伤患者Cys C升高后(&gt;1.03 mg/L)至开始启动CBP的间隔时间进行分组，观察不同间隔时间行CBP对患者肾功能恢复以及预后的影响，为患者CBP时机的选择提供依据。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 研究设计及病例纳入和排除标准</title><p>选取2017年11月~2018年8月期间于承德市中心医院重症医学科行CBP治疗的脓毒症急性肾损伤患者43例。</p><sec id="s4_1_1"><title>2.1.1. 纳入标准</title><p>1) 年龄 ≥ 65岁。2) 脓毒症诊断标准：明确的感染 ＋ SOFA评分 ≥ 2分。3) AKI诊断标准：符合KDIGO指南即：48小时内scr升高超过0.3 mg/dl (26.5 umol/L)；scr升高超过基线1.5倍；尿量小于0.5 ml/kg/h。且持续6小时以上。4) 具有CBP上机指证。</p></sec><sec id="s4_1_2"><title>2.1.2. 排除标准</title><p>1) 既往慢性肾脏病患者、长期血液或腹膜透析患者。2) ICU住院时间 &lt; 48小时。3) 行CBP治疗时间 &lt; 12小时。4) 患有严重免疫缺陷病、血液病、恶性肿瘤、严重代谢性疾病的患者。5) 家属中途放弃。</p></sec></sec><sec id="s4_2"><title>2.2. 研究方法记录</title><p>一般资料：病案号、姓名、性别、年龄、BMI、住院时间及住ICU时间、既往病史等。临床指标：行CBP前后降钙素原、C反应蛋白、血肌酐、胱抑素C水平平均值(采用颗粒增强散射免疫比浊法测定胱抑素C血清水平)、尿量、计算序贯器官衰竭评分sofa、急性病生理学和长期健康APACHE II评分、GCS评分，是否采用机械通气、使用血管活性药物、治疗转归(28天病死率) (Y或D)。所有入选的研究对象于行CBP治疗开始前抽取清晨空腹采集3 ml静脉血以及行CBP后24小时内采静脉血。3000 r/min低速离心15 min，分离血清，取上清液，分装保存于−80摄氏度冰箱待测。采用颗粒增强散射免疫比浊法测定胱抑素C血清水平。</p><p>统计学方法应用SPSS22.0统计学软件对数据进行统计学分析，数量变量采用均数 &#177; 标准差表示，计量资料两组间比较采用独立样本t检验。本组治疗前后比较采用配对样本t检验；组间比较采用t检验/方差分析，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>共纳入老年脓毒症急性肾损伤患者43例。</p><sec id="s5_1"><title>3.1. 结论</title><p>1) A组和B组的年龄，性别，住院时间，BMI，尿量，APACHE II评分，GCS评分，SOFA评分，入院时是否机械通气的例数，是否用血管活性药物的例数，血清胱抑素C (cys-c)，C反应蛋白(CRP)，血清肌酐(scr)，乳酸，降钙素原(PCT) P值均大于0.05如表1~3所示，即以上指标在治疗前A组和B组均无统计学差异。2) A组与B组在治疗后的感染指标血清降钙素原(PCT)、C-反应蛋白(CRP)、急性生理学及慢性健康状况评分(APACHE) II评分中P值 &lt; 0.05如表4所示，即两组之间存在统计学差异，且A组指标明显优于B组。3) A组与B组在治疗后的肾功能恢复指标尿量，血清肌酐(scr)，血清胱抑素C (cys-c)的P值 &lt; 0.05，即存在统计学差异，且A组肾功能恢复水平指标优于B组。4) 28天生存率A组与B组的比P值 &gt; 0.05，即28天生存率两组无统计学意义。结论：胱抑素C升高后12小时内的治疗组比胱抑素C升高后12~24小时内治疗组的炎症因子清除及肾功能恢复方面效果好，但对于患者的生存率并无改变。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of General condition Indexes before treatment between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >分组</th><th align="center" valign="middle"  rowspan="2"  >年龄 (岁，Χ &#177; s<sup>2</sup>)</th><th align="center" valign="middle"  colspan="2"  >性别(例，%)</th><th align="center" valign="middle"  rowspan="2"  >住院时间(天)</th><th align="center" valign="middle"  rowspan="2"  >BMI</th></tr></thead><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >女</td></tr><tr><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >72.5 &#177; 13.8</td><td align="center" valign="middle" >11 (25%)</td><td align="center" valign="middle" >9 (22%)</td><td align="center" valign="middle" >19.1 &#177; 6.9</td><td align="center" valign="middle" >24.1 &#177; 0.9</td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" >67.2 &#177; 8.2</td><td align="center" valign="middle" >11 (25%)</td><td align="center" valign="middle" >12 (28%)</td><td align="center" valign="middle" >18.6 &#177; 4.5</td><td align="center" valign="middle" >23.0 &#177; 2.1</td></tr><tr><td align="center" valign="middle" >t/Χ<sup>2</sup></td><td align="center" valign="middle" >1.14</td><td align="center" valign="middle"  colspan="2"  >0.43</td><td align="center" valign="middle" >0.204</td><td align="center" valign="middle" >1.54</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.27</td><td align="center" valign="middle"  colspan="2"  >0.51</td><td align="center" valign="middle" >0.84</td><td align="center" valign="middle" >0.14</td></tr></tbody></table></table-wrap><p>表1. 两组患者治疗前一般情况指标比较</p><p>A组：胱抑素C升高后12小时内启用CRRT组；B组：胱抑素C升高后12~24小时启用CRRT组。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of clinical parameters before treatment with CRRT in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >分组</th><th align="center" valign="middle"  rowspan="2"  >尿量 (ml/24 h)</th><th align="center" valign="middle"  rowspan="2"  >APACHEII (分)</th><th align="center" valign="middle"  rowspan="2"  >GCS (分)</th><th align="center" valign="middle"  rowspan="2"  >SOFA (分)</th><th align="center" valign="middle"  colspan="2"  >入院时是否机械通气 (例，%)</th><th align="center" valign="middle"  colspan="2"  >是否用血管活性药物 (例，%)</th></tr></thead><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >否</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >31.8 &#177; 5.1</td><td align="center" valign="middle" >21.3 &#177; 5.9</td><td align="center" valign="middle" >12.0 &#177; 3.4</td><td align="center" valign="middle" >5.6 &#177; 3.5</td><td align="center" valign="middle" >10 (23%)</td><td align="center" valign="middle" >10 (23%)</td><td align="center" valign="middle" >10 (23%)</td><td align="center" valign="middle" >10 (23%)</td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" >31.9 &#177; 3.7</td><td align="center" valign="middle" >23.6 &#177; 3.3</td><td align="center" valign="middle" >11.5 &#177; 1.9</td><td align="center" valign="middle" >8.3 &#177; 4.5</td><td align="center" valign="middle" >15 (35%)</td><td align="center" valign="middle" >8 (19%)</td><td align="center" valign="middle" >11 (26%)</td><td align="center" valign="middle" >12 (28%)</td></tr><tr><td align="center" valign="middle" >t/Χ<sup>2</sup></td><td align="center" valign="middle" >−0.18</td><td align="center" valign="middle" >−1.16</td><td align="center" valign="middle" >0.38</td><td align="center" valign="middle" >−2.1</td><td align="center" valign="middle"  colspan="2"  >1.80</td><td align="center" valign="middle"  colspan="2"  >0.03</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.56</td><td align="center" valign="middle" >0.25</td><td align="center" valign="middle" >0.71</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle"  colspan="2"  >0.17</td><td align="center" valign="middle"  colspan="2"  >0.85</td></tr></tbody></table></table-wrap><p>表2. 两组CRRT治疗前临床指标的对比</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of laboratory tests before CRRT treatment between two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >Cys-c (mg/L)</th><th align="center" valign="middle" >CRP (mg/ L)</th><th align="center" valign="middle" >scr (umol/L)</th><th align="center" valign="middle" >Lac (mmol/L)</th><th align="center" valign="middle" >PCT (pg/ml)</th></tr></thead><tr><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >2.7 &#177; 1.0</td><td align="center" valign="middle" >48.89 &#177; 6.4</td><td align="center" valign="middle" >314.2 &#177; 256.4</td><td align="center" valign="middle" >4.5 &#177; 2.4</td><td align="center" valign="middle" >15.2 &#177; 12.4</td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" >3.3 &#177; 0.9</td><td align="center" valign="middle" >54.58 &#177; 0.3</td><td align="center" valign="middle" >333.2 &#177; 121.2</td><td align="center" valign="middle" >4.1 &#177; 1.6</td><td align="center" valign="middle" >14.9 &#177; 4.8</td></tr><tr><td align="center" valign="middle" >t/Χ<sup>2</sup></td><td align="center" valign="middle" >0.38</td><td align="center" valign="middle" >0.58</td><td align="center" valign="middle" >−0.23</td><td align="center" valign="middle" >0.44</td><td align="center" valign="middle" >0.063</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.71</td><td align="center" valign="middle" >0.84</td><td align="center" valign="middle" >0.81</td><td align="center" valign="middle" >0.66</td><td align="center" valign="middle" >0.95</td></tr></tbody></table></table-wrap><p>表3. 两组CRRT治疗前实验室检查指标的对比</p><p>注：Lac为乳酸，APACHE II为急性生理学与慢性健康状况评分系统，GCS为格拉斯哥评分，BMI为体重指数，SOFA为序贯器官衰竭评分，scr为血肌酐，CRP为C反应蛋白，PCT为降钙素原，Cys-c为胱抑素C，P &lt; 0.05。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of infection index, renal function and 28 day survival rate after CBP treatment in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >APACHE II (分)</th><th align="center" valign="middle" >CRP (mg/L)</th><th align="center" valign="middle" >PCT (ng/ml)</th><th align="center" valign="middle" >Scr (μmol/L)</th><th align="center" valign="middle" >Cys-c (mg/L)</th><th align="center" valign="middle" >尿量(mL/24h)</th><th align="center" valign="middle" >28天存活率(例，%)</th></tr></thead><tr><td align="center" valign="middle" >A组</td><td align="center" valign="middle" >13.3 &#177; 0.8</td><td align="center" valign="middle" >4.58 &#177; 0.3</td><td align="center" valign="middle" >3.91 &#177; 1.9</td><td align="center" valign="middle" >152.3 &#177; 124.5</td><td align="center" valign="middle" >1.44 &#177; 0.65</td><td align="center" valign="middle" >300.9 &#177; 6.1</td><td align="center" valign="middle" >19 (90.0)</td></tr><tr><td align="center" valign="middle" >B组</td><td align="center" valign="middle" >19.2 &#177; 5.3</td><td align="center" valign="middle" >7.9 &#177; 2.4</td><td align="center" valign="middle" >5.75 &#177; 3.9</td><td align="center" valign="middle" >268.3 &#177; 118.4</td><td align="center" valign="middle" >2.86 &#177; 0.82</td><td align="center" valign="middle" >121.9 &#177; 3.7</td><td align="center" valign="middle" >18 (61.5)</td></tr><tr><td align="center" valign="middle" >t/Χ<sup>2</sup></td><td align="center" valign="middle" >−3.3</td><td align="center" valign="middle" >−1.9</td><td align="center" valign="middle" >−2.1</td><td align="center" valign="middle" >−2.2</td><td align="center" valign="middle" >−4.3</td><td align="center" valign="middle" >3.6</td><td align="center" valign="middle" >2.37</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >0.046</td><td align="center" valign="middle" >0.033</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.12</td></tr></tbody></table></table-wrap><p>表4. 两组经CBP治疗后的感染指标、肾功能以及28天生存率对比</p></sec><sec id="s5_2"><title>3.2. 讨论</title><p>脓毒症是重症医学科常见的危重疾病，对于老年人这种基础状态整体降低的群体，以及免疫能力的下降引起致病菌感染的危险性显著增加。老年患者感染症状的隐匿性，脓毒症的集束化治疗很可能被延误 [<xref ref-type="bibr" rid="hanspub.27452-ref7">7</xref>] 。且这类人群脓毒症进展迅速，易早期引起血流动力学不稳定，老年患者还存在免疫衰老的突出特点，CRRT的早期介入可以起到免疫调剂的作用 [<xref ref-type="bibr" rid="hanspub.27452-ref8">8</xref>] 。因此合适的CRRT治疗时机对于老年患者显得尤为重要。因此本研究选择的对象重点是脓毒症老年患者 [<xref ref-type="bibr" rid="hanspub.27452-ref9">9</xref>] ，而生物学标记物胱抑素C (Cys-C)目前已经可以用来做AKI早期诊断和预后评价，Cys-C无组织学特异性，在所有的有核细胞中均能表达，机体内产量恒定，且它是一种低分子量蛋白质，最终唯一的代谢清除途径是肾脏。理论上C它是一种理想的反映CFR变化的内源性标记物 [<xref ref-type="bibr" rid="hanspub.27452-ref10">10</xref>] 。亦有研究显示，Cys C是预测重症监护室患者发生AKI的良好标志物。关于脓毒症AKI开始治疗时机标准尚未有明确的界定，临床广泛对于脓毒症AKI患者的上机时间仍然遵循2012年KDIGO标准，即以血肌酐和尿量来判断，这两个指标具有明显的滞后性，本论文进一步探讨早期肾损伤因子标记物胱抑素C在上机时机的价值。目前有文献研究发现在肾功能恢复的研究中，年龄具有统计学意义，因此为了除外年龄对结果的影响，本文将脓毒症老年患者设为研究对象。本研究发现，以胱抑素C为节点来早期启动老年脓毒症患者行CBP治疗可以提高炎症因子如降钙素原(PCT)、C-反应蛋白(CRP)这些因子的清除率，这与陈绵军等人 [<xref ref-type="bibr" rid="hanspub.27452-ref11">11</xref>] 在连续性肾脏替代治疗对老年脓毒症患者的疗效分析中提到的研究结论具有一致性。本研究发现以胱抑素C来早期启动老年脓毒症患者行CBP治疗可以改善肾脏功能的恢复。本研究发现两组之间的生存率是无统计学差异的，也就是说应用胱抑素C来启动老年脓毒症急性肾损伤患者行CPB的时机对于患者的生存率并无改善。但由于本研究数量较少，可提供的证据不足，关于胱抑素C是否可以成为比血肌酐更好评估上机时机的标准也有待于后面学者的进一步研究。</p></sec></sec><sec id="s6"><title>文章引用</title><p>刘 阳,周景霞,刘春涛,周大鹏. 胱抑素C在老年脓毒症急性肾损伤患者中启动CBP治疗时机的价值The Value of Cystatin C in Initiating Continuous Blood Purification in Elderly Patients with Acute Renal Injury Due to Sepsis[J]. 临床医学进展, 2018, 08(09): 813-818. https://doi.org/10.12677/ACM.2018.89136</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.27452-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Keum, H.R., Jang, S., Park, J.M., Kang, J., et al. (2016) Short and Long-Term Mortality Rates of Elderly Acute Kidney Injury Patients Who Underwent Continuous Renal Replacement Therapy. PLoS ONE, 11, 1-12.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0167067</mixed-citation></ref><ref id="hanspub.27452-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王旭涛, 陈燕启. 老年脓毒症患者预后相关因素的探讨[J]. 内科急危重症杂志, 2017, 23(1): 23-25.</mixed-citation></ref><ref id="hanspub.27452-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ethgen, O., Schneider, A.G., Bagshaw, S.M., Bellomo, R. and Kellum, J.A. (2015) Economics of Dialysis Dependence Following Renal Replacement Therapy for Critically Ill Acute Kidney Injury Patients. Nephrology Dialysis Transplantation, 30, 54-61. &lt;br&gt;https://doi.org/10.1093/ndt/gfu314</mixed-citation></ref><ref id="hanspub.27452-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">郭锦洲. 改善全球肾脏病预后组织(KDIGO)临床实践指南: 急性肾损伤[J]. 肾脏病与透析肾移植杂志, 2013, 22(1): 57-60.</mixed-citation></ref><ref id="hanspub.27452-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">李林, 黄莉. 基于血清胱抑素C水平的脓毒症性急性肾损伤患者连续肾替代疗法启动时机研究[J]. 中国全科医学, 2017, 20(17): 2127-2130.</mixed-citation></ref><ref id="hanspub.27452-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Starr, M.E. and Saito, H. (2014) Sepsis in Old Age: Review of Human and Animal Studies. Aging and Disease, 5, 126-136.</mixed-citation></ref><ref id="hanspub.27452-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">刘超, 毛智, 周飞虎. 老年脓毒症的研究进展[J]. 解放军医学杂志, 2017, 42(6): 563-568.</mixed-citation></ref><ref id="hanspub.27452-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lu, F.P., Chen, W., Zhen, J., et al. (2016) Changes of Lymphocyte Subsets in Elderly Patients with Sepsis before and after Immune Modulation Diagnosing and Managing Sepsis in Older Adults. Expert Review of Anti-infective Therapy, 14, 231-241. &lt;br&gt;https://doi.org/10.1586/14787210.2016.1135052</mixed-citation></ref><ref id="hanspub.27452-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Per-alta, C.A., Katz, R. and Sarnak, M.J. (2008) Cyst at in C Identifies Chronic Kidney Disease Patients at Higher Risk for Complic at Ions. Ann Clin Lab Sci, 22, 931-932.</mixed-citation></ref><ref id="hanspub.27452-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z., Lu, B., Sheng, X., et al. (2011) Cystatin C in Prediction of Acute Kidney Injury: A Systemic Review and Mete-Analysis. American Journal of Kidney Diseases, 58, 356-365. &lt;br&gt;https://doi.org/10.1053/j.ajkd.2011.02.389</mixed-citation></ref><ref id="hanspub.27452-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">陈绵军, 陈军, 谭德敏, 等. 连续性肾脏替代治疗对老年脓毒症患者疗效分析[J]. 中华老年多器官疾病杂志, 17(3): 211-215.</mixed-citation></ref></ref-list></back></article>